Share on LinkedInShare on LinkedIn

ARTICLE · 10 JANUARY 2018

Declarations As New Evidence To Overcome § 325(d)

Jones Day
Jones Day
Contributor
Jones Day

Jones Day

Jones Day is a global law firm with more than 2,400 lawyers in 40 offices across five continents....

View firm profile
Explore more from Jones Day

We have published other blog postings relating to 35 U.S.C. §325(d), including a blog posting that addresses the PTAB's October 24, 2017 notice designating three of its decisions as informative (here).

United StatesIntellectual Property

We have published other blog postings relating to 35 U.S.C. §325(d), including a blog posting that addresses the PTAB's October 24, 2017 notice designating three of its decisions as informative (here).  Recently, the PTAB instituted an inter partes review of US Patent No. 7,049,328 (the "'328 patent") issued to Apotex Technologies, Inc. (IPR2017-01446) in view of a reference the USPTO had already considered during prosecution.

The '328 patent is directed to using deferiprone, an iron chelating drug, to treat patients who require regular transfusions of red blood cells by stabilizing or reducing iron overload in their hearts.  Claim 1 is illustrative of the challenged claims and recites:

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from